A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

Back to Search
Print
Bookmark Trial

NCT00625833

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Anniston, Alabama, 36207, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Diabetic Neuropathies
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female of any race at least 18 years of age

- Diagnosis of painful, distal, symmetrical, sensory-motor polyneuropathy, which is due to diabetes, for at least 1 year

- Patients at Visit 1 must have a score ≥40 mm on the Pain Visual Analogue Scale

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with significant hepatic impairment


- Neurological disorders unrelated to diabetic neuropathy that may confuse the
assessment of neuropathic pain


- Any pain or other condition that may confound assessment or self-evaluation of the
pain due to diabetic neuropathy


- Amputations other than toes


- A current or recent diagnosis (past 6 months) or episode of major depressive disorder
and/or uncontrolled depression


- History of transient ischemic attack or stroke


- Myocardial infarction or unstable angina within the past three months

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Diabetic NeuropathiesA Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy
NCT00644748
  1. Fortaleza, Ceara
  2. Taguatinga, DF
  3. Belo Horizonte, MG
  4. Curitiba, Parana
  5. Recife, Pernambuco
  6. Rio de Janeiro, RJ
  7. Porto Alegre, RS
  8. Sao Paulo, SP
  9. Sao Paulo, SP
ALL GENDERS
51 Years+
years
MULTIPLE SITES
Diabetic NeuropathiesPregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT00143156
  1. Tuscaloosa, Alabama
  2. Phoenix, Arizona
  3. Little Rock, Arkansas
  4. La Mesa, California
  5. Los Gatos, California
  6. Northridge, California
  7. Tustin, California
  8. Walnut Creek, California
  9. Boulder, Colorado
  10. Wheatridge, Colorado
  11. New Haven, Connecticut
  12. Clearwater, Florida
  13. Hollywood, Florida
  14. Ocala, Florida
  15. Tampa, Florida
  16. West Palm Beach, Florida
  17. Atlanta, Georgia
  18. Atlanta, Georgia
  19. Atlanta, Georgia
  20. Decatur, Georgia
  21. Chicago, Illinois
  22. Chicago, Illinois
  23. Peoria, Illinois
  24. Springfield, Illinois
  25. Indianapolis, Indiana
  26. Lexington, Kentucky
  27. Baltimore, Maryland
  28. Boston, Massachusetts
  29. Boston, Massachusetts
  30. Springfield, Massachusetts
  31. Jackson, Mississippi
  32. Tupelo, Mississippi
  33. Jefferson City, Missouri
  34. St Louis, Missouri
  35. St. Louis, Missouri
  36. Omaha, Nebraska
  37. Englewood, New Jersey
  38. Shrewsbury, New Jersey
  39. New Hyde Park, New York
  40. New York, New York
  41. New York, New York
  42. Kettering, Ohio
  43. Toledo, Ohio
  44. Tulsa, Oklahoma
  45. Warwick, Rhode Island
  46. Memphis, Tennessee
  47. Dallas, Texas
  48. Frisco, Texas
  49. Houston, Texas
  50. San Antonio, Texas
  51. San Antonio, Texas
  52. Salt Lake City, Utah
  53. Burlington, Vermont
  54. Charlottesvlle, Virginia
  55. Ponce,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Diabetic NeuropathiesA Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
NCT00625833
  1. Anniston, Alabama
  2. Birmingham, Alabama
  3. Mission Viejo, California
  4. Denver, Colorado
  5. New Britain, Connecticut
  6. Waterbury, Connecticut
  7. Tampa, Florida
  8. Winter Haven, Florida
  9. Lexington, Kentucky
  10. Louisville, Kentucky
  11. North Dartmouth, Massachusetts
  12. Jackson, Mississippi
  13. Tupelo, Mississippi
  14. Marionville, Missouri
  15. Springfield, Missouri
  16. Elizabeth, New Jersey
  17. Hamilton, New Jersey
  18. Buffalo, New York
  19. New York, New York
  20. New York, New York
  21. Cranston, Rhode Island
  22. Cumberland, Rhode Island
  23. Myrtle Beach, South Carolina
  24. Bartlett, Tennessee
  25. Beaumont, Texas
  26. Beaumont, Texas
  27. Dallas, Texas
  28. Dallas, Texas
  29. Dallas, Texas
  30. Houston, Texas
  31. Houston, Texas
  32. Milwaukee, Wisconsin
  33. Brno,
  34. Ceske Budejovice,
  35. Ostrava,
  36. Zlin,
  37. Helsinki,
  38. Kokkola,
  39. Lahti,
  40. Lohja,
  41. Almere,
  42. Amsterdam,
  43. Venlo,
  44. Worcester, Cape Town
  45. Bloemfontein, Free State
  46. Ennerdale, Gauteng
  47. Tshwane, Gauteng
  48. Stanger, Kwa- Zulu Natal
  49. Durban, KwaZulu Natal
  50. Cape Town,
  51. L'hospitalet de Llobregat, Barcelona
  52. Santiago de Compostela, LA Coruña
  53. Barcelona,
  54. Madrid,
  55. Pontevedra,
  56. Valencia,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
Official Title  ICMJE A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
Brief Summary This is a trial to investigate the effectiveness and safety of [S,S]-Reboxetine in relieving chronic peripheral pain suffered by patients with diabetes. Some evidence for the effectiveness of [S,S]- Reboxetine in relieving chronic pain has been seen in 3 completed trials.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Diabetic Neuropathies
Intervention  ICMJE
  • Drug: Placebo
    Oral tablet once a day dosing for 10 weeks.
  • Drug: [S,S]-Reboxetine
    Oral tablet once a day dosing for 10 weeks.
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: 2
    Intervention: Drug: [S,S]-Reboxetine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: February 19, 2008)		330
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE November 2008
Actual Primary Completion Date November 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female of any race at least 18 years of age
  • Diagnosis of painful, distal, symmetrical, sensory-motor polyneuropathy, which is due to diabetes, for at least 1 year
  • Patients at Visit 1 must have a score ?40 mm on the Pain Visual Analogue Scale

Exclusion Criteria:

  • Patients with significant hepatic impairment
  • Neurological disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathic pain
  • Any pain or other condition that may confound assessment or self-evaluation of the pain due to diabetic neuropathy
  • Amputations other than toes
  • A current or recent diagnosis (past 6 months) or episode of major depressive disorder and/or uncontrolled depression
  • History of transient ischemic attack or stroke
  • Myocardial infarction or unstable angina within the past three months
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Czechia,   Finland,   Netherlands,   South Africa,   Spain,   United States
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT00625833
Other Study ID Numbers  ICMJE A6061037
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP